|
Mechanism5-HT7 receptor antagonists |
|
|
|
|
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1/2 A double-blind, randomized, adaptive, vehicle controlled first in-human phase 1-2a trial to determine the safety, pharmacokinetics, and efficacy of PRA-523 against pruritus secondary to atopic dermatitis
100 Clinical Results associated with Praeventix, Inc.
0 Patents (Medical) associated with Praeventix, Inc.
100 Deals associated with Praeventix, Inc.
100 Translational Medicine associated with Praeventix, Inc.